Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Protagenic Therapeutics(PTIX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PTIX
09/14/2026: PTIX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Protagenic Therapeutics is a clinical-stage biotechnology company focused on developing synthetic peptide-based treatments for stress and metabolic disorders. Its primary strength lies in a specialized research platform aimed at high-need medical conditions, though it currently lacks product revenue and faces significant clinical execution risks. The core investment story centers on the potential for its lead asset, PT00114, to succeed in clinical trials and gain eventual regulatory approval. Investors should monitor clinical trial updates and the company's cash runway, as it is highly dependent on external funding. The stock suits risk-tolerant investors seeking speculative growth in the biotech sector rather than those looking for income or value.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward potential based on clinical success rather than established growth metrics. |
| Momentum investor | Mixed fit | Momentum may occur around clinical trial data releases, but the stock lacks the consistent volume and trend of mature equities. |
| Value investor | Weak fit | There are no traditional value metrics like P/E or earnings to support a value-based investment thesis. |
| Dividend investor | Weak fit | The company is in an early development phase and does not provide income through dividends. |
| Low-risk investor | Weak fit | High clinical, financial, and market volatility make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks often experience sharp price swings based on news cycles and dilution events. |
| Valuation risk | High | Valuations are highly speculative as there are no current earnings or revenues to provide a floor. |
| Competition risk (CNS/Metabolic) | High | Established players with significant resources have multiple products targeting similar conditions. |
| Business quality | Medium | While the technology is novel, the company lacks a proven track record of successful commercialization. |
| Dividend income | Low / none | Investors should expect no dividend income for the foreseeable future. |
| Execution risk | High | Clinical trial success is highly uncertain and requires perfect execution over many years. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -59.13% | Avg. Invested days 14 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/14/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.58M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 22.2K shares | Beta 0.38 | 52 Weeks Range 0.13 - 4.55 | Updated Date 09/13/2026 |
52 Weeks Range 0.13 - 4.55 | Updated Date 09/13/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13.13 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development | Research and potential future commercialization of synthetic peptide hormones. | The company does not currently generate revenue; it burns cash to research drugs that may be profitable in the future. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3.36M | Price to Sales(TTM) - |
Enterprise Value 3.36M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 0.06 | Enterprise Value to EBITDA -0.64 | Shares Outstanding 1.81M | Shares Floating 1.72M |
Shares Outstanding 1.81M | Shares Floating 1.72M | ||
Percent Insiders 6.2 | Percent Institutions 4.64 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Protagenic Therapeutics
Exchange NASDAQ | Headquarters New York, NY, United States | ||
IPO Launch date 2016-01-05 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.protagenic.com |
Full time employees 2 | Website https://www.protagenic.com | ||
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. The company was founded in 2004 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.